Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Maxcyte Inc (MXCT)

Maxcyte Inc (MXCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
MaxCyte Completes Operational Review, Adjusts Workforce, and Raises 2024 Revenue Guidance

MaxCyte completes operational review, streamlines workforce, increases 2024 revenue guidance, and focuses on cell therapy innovation.Quiver AI SummaryMaxCyte, Inc. has completed an internal operational...

MXCT : 4.19 (-1.87%)
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

MXCN.LN : 680.000 (unch)
MXCT.LN : 346.000 (+0.87%)
MXCT : 4.19 (-1.87%)
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

MXCN.LN : 680.000 (unch)
MXCT.LN : 346.000 (+0.87%)
MXCT : 4.19 (-1.87%)
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

MXCN.LN : 680.000 (unch)
MXCT.LN : 346.000 (+0.87%)
MXCT : 4.19 (-1.87%)
MaxCyte to Participate in Two Upcoming Investor Conferences

MXCN.LN : 680.000 (unch)
MXCT.LN : 346.000 (+0.87%)
MXCT : 4.19 (-1.87%)
MaxCyte Appoints Cynthia Collins to its Board of Directors

PSTX : 9.44 (-0.63%)
MXCN.LN : 680.000 (unch)
DMTKQ : 0.0001 (unch)
MXCT.LN : 346.000 (+0.87%)
MXCT : 4.19 (-1.87%)
CERT : 10.92 (-4.21%)
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

MXCN.LN : 680.000 (unch)
MXCT.LN : 346.000 (+0.87%)
MXCT : 4.19 (-1.87%)
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

MXCN.LN : 680.000 (unch)
MXCT.LN : 346.000 (+0.87%)
MXCT : 4.19 (-1.87%)
Why Shares of MaxCyte Are Plummeting on Thursday

The biotech company reduced full-year guidance and expects so-so third-quarter revenue.

MXCT : 4.19 (-1.87%)
Nasdaq Futures Slip as Bond Yields Rebound, U.S. Jobs Report Looms

December Nasdaq 100 E-Mini futures (NQZ23) are trending down -0.10% this morning after three major U.S. benchmark indices closed higher on Wednesday as the latest batch of U.S. economic data prompted investors...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
MSFT : 437.39 (-3.76%)
AMZN : 220.52 (-4.60%)
META : 597.19 (-3.59%)
PLTR : 71.51 (-3.87%)
PSX : 111.86 (-3.43%)
MRO : 28.55 (-1.28%)
CALM : 103.53 (-2.93%)
PNDOR.C.DX : 1,274.500 (+0.79%)
MXCT : 4.19 (-1.87%)
BB : 3.01 (-5.94%)

Barchart Exclusives

2 Dividend Stocks Analysts Love for Fat Yields in 2025
These companies have high yields and have strong business models that position them to maintain and potentially increase their dividend payments in 2025. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar